| Literature DB >> 35174731 |
Lindsay Tetreault1, Oliver Mowforth2, Danyal Z Khan2, Toto Gronlund, Philip Garwood3, Olesja Hazenbiller4, James S Harrop5, Bizhan Aarabi6, Vafa Rahimi-Movaghar7, Shekar N Kurpad8, James D Guest9, Jefferson R Wilson10, Brian K Kwon11, Michael G Fehlings10, Benjamin M Davies2,11, Mark R N Kotter2,11.
Abstract
STUDYEntities:
Keywords: James Lind Alliance; degenerative cervical myelopathy; priority setting partnership; research uncertainties; surveys and questionnaires
Year: 2022 PMID: 35174731 PMCID: PMC8859709 DOI: 10.1177/21925682211062501
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Figure 1.An overview of the priority setting partnership process as outlined by the James Lind Alliance.
Important Terminology.
| Term | Definition |
|---|---|
| Research uncertainty | •Submitted by health care professionals and individuals with lived experience via survey |
| •Any important question about health care that cannot be answered by the existing body of evidence. Specifically, there are either no up-to-date, reliable systematic reviews or clinical practice guidelines that answer the question, or current evidence indicates that uncertainty exists | |
| •In this paper, the term “research uncertainty” is used interchangeably with survey response, survey submission, evidence uncertainty and in-scope question | |
| Summary question | •Developed by the information specialist with input from the steering committee |
| •An overarching question that summarizes similar submitted research uncertainties | |
| Research priority | •A summary question that is deemed to be one of the most important and should be answered by future research |
| Individuals with lived experience | •An individual either diagnosed with or treated for degenerative cervical myelopathy or a caregiver/supporter |
Figure 2.An overview of the process from initial survey results to the top ten research priorities.
The Top Ten Research Priorities for Degenerative Cervical Myelopathy.
| 1. What strategies can increase awareness and understanding of DCM amongst health care professionals and the public? Can these strategies help improve timely diagnosis and management of DCM? |
| 2. What is the natural history of DCM? What is the relationship between DCM and asymptomatic spinal cord compression or canal stenosis? What factors influence the natural history of the disease? |
| 3. What are the diagnostic criteria of DCM? What is the role of imaging and when should imaging be used in the assessment of DCM? |
| 4. What assessment tools can be used to evaluate functional impairment, disability and quality of life in people with DCM? What instruments, tools or methods can be used or developed to monitor people with DCM for disease progression or improvement either before or after surgical treatment? |
| 5. What is the pathophysiology of DCM? What are the mechanisms of neurological injury and the molecular and anatomical consequences? |
| 6. What is the role of rehabilitation following surgery for DCM? Can structured postoperative rehabilitation improve outcome following surgery for DCM? What are the most effective strategies? |
| 7. Can novel therapies, including stem-cell, gene, pharmacological and neuroprotective therapies, improve the health and wellbeing of people living with DCM and slow down disease progression? |
| 8. What is the socio-economic impact of DCM? |
| 9. What is the role of dynamic or novel imaging techniques and neurophysiology in the assessment of DCM? |
| 10. Are there clinical and imaging factors that can help a surgeon select who should undergo surgical decompression in the setting of DCM? At what stage of the disease is surgery the preferred management strategy? |